Pulmonx Corporation (LUNG)
Treats severe emphysema using minimally invasive valve implants inserted through the lungs.
$1.29+0.06%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-19.9%
The outlook
Pulmonx is trading near its 52-week lows at $1.29, well below both its 50- and 200-day moving averages, reflecting a downward trend. Analyst coverage remains bullish on fundamentals, with an average price target implying significant upside, though the stock's recent weakness suggests current sentiment lags that longer-term view.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range7% of the way from its 52-week low to high
Price targetAvg target +164% vs current price
Analyst price target
~12-month · 5 analysts$3.40average target+163.6% vs now
Now $1.29
Low $2.50High $5.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$54.5M
52-wk high
$3.39
52-wk low
$1.13
50-day avg
$1.41
200-day avg
$1.61
Trailing P/E
—